Literature DB >> 17145876

Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer.

Ling Geng1, Kyle C Cuneo, Allie Fu, Tianxiang Tu, Peter W Atadja, Dennis E Hallahan.   

Abstract

Histone deacetylases (HDAC) have been identified as therapeutic targets due to their regulatory function in DNA structure and organization. LBH589 is a novel inhibitor of class I and II HDACs. We studied the effect of LBH589 and ionizing radiation (IR) on DNA repair in two human non-small cell lung cancer (NSCLC) cell lines (H23 and H460). gamma-H2AX foci present at DNA double-strand breaks (DSBs) were detected in the nuclei following 3 Gy irradiation for up to 6 hours. LBH589 administered before irradiation increased the duration of gamma-H2AX foci beyond 24 hours. Furthermore, radiation alone induced translocation of HDAC4 to the nucleus. In contrast, treatment with LBH589 followed by irradiation resulted in HDAC4 confinement to the cytoplasm, indicating that HDAC inhibition affects the nuclear localization of HDAC4. The findings that LBH589 confines HDAC4 to the cytoplasm and increases the duration of gamma-H2AX foci in irradiated cell lines suggest that HDAC4 participates in DNA damage signaling following IR. Annexin-propidium iodide flow cytometry assays, cell morphology studies, and cleaved caspase-3 Western blot analysis revealed a synergistic effect of LBH589 with IR in inducing apoptosis. Clonogenic survival showed a greater than additive effect when LBH589 was administered before irradiation compared with irradiation alone. In vivo tumor volume studies showed a growth delay of 20 days with combined treatment compared with 4 and 2 days for radiation or LBH589 alone. This study identifies HDAC4 as a biomarker of LBH589 activity and recognizes the ability of LBH589 to sensitize human NSCLC to radiation-induced DNA DSBs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17145876     DOI: 10.1158/0008-5472.CAN-06-0049

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  69 in total

Review 1.  Lung cancer therapeutics that target signaling pathways: an update.

Authors:  M Roshni Ray; David Jablons; Biao He
Journal:  Expert Rev Respir Med       Date:  2010-10       Impact factor: 3.772

2.  HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination.

Authors:  Shanthi Adimoolam; Mint Sirisawad; Jun Chen; Patti Thiemann; James M Ford; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-27       Impact factor: 11.205

3.  Histone deacetylase inhibitors in the treatment for multiple myeloma.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Int J Hematol       Date:  2013-03-10       Impact factor: 2.490

4.  Contribution of decreased expression of Ku70 to enhanced radiosensitivity by sodium butyrate in glioblastoma cell line (U251).

Authors:  Yuhui Li; Hongxia Zhou; Enming Xing; Meera Dassarath; Jinghua Ren; Xiaorong Dong; Hongli Liu; Kunyu Yang; Gang Wu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-06-14

Review 5.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

6.  Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases.

Authors:  A Lahm; C Paolini; M Pallaoro; M C Nardi; P Jones; P Neddermann; S Sambucini; M J Bottomley; P Lo Surdo; A Carfí; U Koch; R De Francesco; C Steinkühler; P Gallinari
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-23       Impact factor: 11.205

7.  The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells.

Authors:  Anna Scuto; Mark Kirschbaum; Claudia Kowolik; Leo Kretzner; Agnes Juhasz; Peter Atadja; Vinod Pullarkat; Ravi Bhatia; Stephen Forman; Yun Yen; Richard Jove
Journal:  Blood       Date:  2008-03-18       Impact factor: 22.113

8.  A role for the histone deacetylase HDAC4 in the life-cycle of HIV-1-based vectors.

Authors:  Johanna A Smith; Jennifer Yeung; Gary D Kao; René Daniel
Journal:  Virol J       Date:  2010-09-16       Impact factor: 4.099

Review 9.  Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents.

Authors:  Jiahuai Tan; Shundong Cang; Yuehua Ma; Richard L Petrillo; Delong Liu
Journal:  J Hematol Oncol       Date:  2010-02-04       Impact factor: 17.388

10.  Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells.

Authors:  Taofeek K Owonikoko; Suresh S Ramalingam; Beatriz Kanterewicz; Trent E Balius; Chandra P Belani; Pamela A Hershberger
Journal:  Int J Cancer       Date:  2010-02-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.